Food and Drug Administration (FDA) approval of Casgevy for TDT, which further underscores the technology’s potential to cure previously untreatable diseases.”
Eric Rhodes, CEO at ERS Genomics, believes the field will keep growing in 2024: “ The CRISPR/Cas9 sector is poised to continue its remarkable growth trajectory through 2024, driven by the first approved clinical application in the U.K. for treating sickle-cell disease and transfusion-dependent beta-thalassemia (TDT). Strengthening this prediction is the recent U.S. Food and Drug Administration (FDA) approval of Casgevy for TDT, which further underscores the technology’s potential to cure previously untreatable diseases.”